ABSTRACT
BACKGROUND/AIMS: We aimed to evaluate the impact of non-alcoholic fatty liver disease (NAFLD) on viral kinetics and virologic response to tenofovir and entecavir treatment in patients with chronic hepatitis B virus (HBV) infection. MATERIALS AND METHODS: This study was designed as a retrospective multicenter cohort study. The impact of hepatosteatosis on pre-treatment serum HBV DNA levels and also on the virologic response to either tenofovir or entecavir at 6 and 12 months of therapy was investigated. RESULTS: A total of 145 cases were involved in the study [median age 40 (18-73) years, 90 (62%) males]. In multivariate analysis, it was detected that patients with NAFLD were older and had a higher body mass index (BMI) [Odds ratio (95% confidence interval) and p-value for age were 1.040 (1.003-1.079) and 0.033 and for BMI were 1.348 (1.190-1.528) and 0.0001, respectively]. When only the 43 patients who were younger than 35.5 years old and who had a BMI less than 27.59 were investigated, serum high-density lipoprotein (HDL) levels and serum HBV DNA levels were lower in patients with NAFLD in multivariate analysis [Odds ratio (95% confidence interval) and p-values for serum HDL level and HBV DNA level were 0.864 (0.061-0.980) and 0.023 and 0.995 (0.990-0.999) and 0.025, respectively]. Totally, 57 and 75 of the patients had received entecavir and tenofovir, respectively. CONCLUSION: Viral replication decreases in patients with chronic HBV infection in the presence of NAFLD, and NAFLD had no impact on the virologic response to entecavir and tenofovir treatment.
Subject(s)
Antiviral Agents/pharmacology , Guanine/analogs & derivatives , Hepatitis B virus/physiology , Hepatitis B, Chronic/drug therapy , Non-alcoholic Fatty Liver Disease/virology , Tenofovir/pharmacology , Adult , Age Factors , Aged , DNA, Viral/blood , Female , Guanine/pharmacology , Hepatitis B virus/genetics , Hepatitis B, Chronic/blood , Hepatitis B, Chronic/virology , Humans , Lipoproteins, HDL/blood , Male , Middle Aged , Non-alcoholic Fatty Liver Disease/blood , Odds Ratio , Retrospective Studies , Treatment Outcome , Virus Replication/drug effects , Young AdultSubject(s)
Antiviral Agents/therapeutic use , Hepacivirus/drug effects , Hepatitis C, Chronic/drug therapy , Interferons/therapeutic use , Poverty , Ribavirin/therapeutic use , Adult , Aged , Biomarkers/blood , Drug Therapy, Combination , Female , Genotype , Hepacivirus/genetics , Hepatitis C, Chronic/diagnosis , Humans , Male , Middle Aged , RNA, Viral/blood , Recurrence , Retreatment , Time Factors , Treatment Outcome , Turkey , Viral LoadSubject(s)
Blood Platelets/virology , Hepatitis, Chronic/blood , Hepatitis, Viral, Human/blood , Mean Platelet Volume , Fatty Liver/blood , Fatty Liver/virology , Hepatitis, Chronic/diagnosis , Hepatitis, Chronic/virology , Hepatitis, Viral, Human/diagnosis , Hepatitis, Viral, Human/virology , Humans , Insulin Resistance , Logistic Models , Odds Ratio , Predictive Value of TestsABSTRACT
BACKGROUND: Effects of whole cell type immunization on mice Ehrlich tumours were evaluated. MATERIALS AND METHODS: After preliminary study, mice were divided two major groups; 1 x 1000 and 100 x 1000 live Ehrlich cell transferred major groups, each divided into four subgroups (n: 10). Study groups were immunized with Ehrlich cell lysates in 0, 3, 7, 14th days and after 30 days of last immunization, live Ehrlich cells were transferred. Mice were observed for six months and evaluated for total and cancer free days. RESULTS: Out of 100 x 1000 cell transferred solid type study group, all study group mean and tumour free periods were statistically longer than control groups. All 1 x 1000 Ehrlich cell transferred study groups survived significantly longer than 100 x 1000 Ehrlich cell transferred groups. CONCLUSIONS: Ehrlich mice tumours were prevented and survival prolonged with whole cell type immunization. Effects are related to the number of transferred tumor cells.
Subject(s)
Ascites , Carcinoma, Ehrlich Tumor/prevention & control , Cell- and Tissue-Based Therapy , Immunization , Animals , Carcinoma, Ehrlich Tumor/immunology , Carcinoma, Ehrlich Tumor/mortality , Female , Mice , Mice, Inbred BALB C , Survival Rate , Tumor Cells, CulturedABSTRACT
AIMS: We aimed to determine whether mean platelet volume (MPV) is one of the variables that determine the severity of liver fibrosis and inflammation. MATERIALS AND METHODS: Patients with chronic hepatitis B virus (HBV) infection were divided into two groups: patients with fibrosis scores of 0-3 and 4-6 and patients with histologic activity index scores of 0-9 and 10-18 (according to the Ishak Scoring System). The independent variables determining the severity of liver fibrosis and inflammation were investigated. RESULTS: Two hundred and thirty-eight patients were included in this retrospective study. The fibrosis scores of 29 patients (12.2%) were higher than 3. The independent variables that determined the severity of the fibrosis score were a high level of serum γ-glutamyl transferase and a low blood platelet count (odds ratio and P values were 1.016 and 0.004 for γ-glutamyl transferase, and 0.986 and 0.002 for blood platelet count). The histologic activity indexes of 38 patients (16%) were higher than 9. The independent variables determining the severity of liver inflammation were serum HBV DNA, γ-glutamyl transferase, and globulin levels and the MPV [odds ratio and P values were, respectively, 0.1001 and 0.046 for HBV DNA (×10); 1.016 and 0.004 for γ-glutamyl transferase; 2.247 and 0.039 for globulin; and 1.488 and 0.004 for the MPV]. The sensitivity, specificity, and positive predictive value and negative predictive value of the model predicting the severity of liver inflammation were 60.5, 83, 40.3, and 91.7%, respectively (area under the receiver-operating characteristic curve=0.775, P=0.0001). CONCLUSION: MPV may provide useful information to predict the degree of liver inflammation along with other markers.
